Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging.

[1]  J. Kereiakes,et al.  The method of linear programming applied to radiation treatment planning. , 1968, Radiology.

[2]  L. Hodes.  Semiautomatic optimization of external beam radiation treatment planning. , 1974, Radiology.

[3]  Biological implications of microdosimetry , 1974 .

[4]  J J Weinkam,et al.  Automatic variation of field size and dose rate in rotation therapy. , 1977, International journal of radiation oncology, biology, physics.

[5]  M. Zaider,et al.  RBEOER: a FORTRAN program for the computation of RBEs, OERs, survival ratios, and the effects of fractionation using the theory of dual radiation action , 1978 .

[6]  K. Uğurbil,et al.  NMR chemical shift imaging in three dimensions. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A Brahme,et al.  Dosimetric precision requirements in radiation therapy. , 1984, Acta radiologica. Oncology.

[8]  R G Dale,et al.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.

[9]  J. Schenck,et al.  An efficient, highly homogeneous radiofrequency coil for whole-body NMR imaging at 1.5 T , 1985 .

[10]  D. Ballon,et al.  31P NMR spectra of extremity sarcomas: Diversity of metabolic profiles and changes in response to chemotherapy , 1990, Magnetic resonance in medicine.

[11]  J. Shapiro,et al.  Large scale optimization of beam weights under dose-volume restrictions. , 1990, International journal of radiation oncology, biology, physics.

[12]  M. Dewhirst,et al.  Soft-tissue sarcomas: MR imaging and MR spectroscopy for prognosis and therapy monitoring. Work in progress. , 1990, Radiology.

[13]  J. Roy,et al.  CT-based optimized planning for transperineal prostate implant with customized template. , 1991, International journal of radiation oncology, biology, physics.

[14]  I. Rosen,et al.  Treatment plan optimization using linear programming. , 1991, Medical physics.

[15]  R. Sloboda,et al.  Optimization of brachytherapy dose distributions by simulated annealing. , 1992, Medical physics.

[16]  J A Frank,et al.  Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. , 1992, Radiology.

[17]  Anderson.  Plan Optimization and Dose Evaluation in Brachytherapy. , 1993, Seminars in radiation oncology.

[18]  J. Kurhanewicz,et al.  Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study , 1993, Magnetic resonance in medicine.

[19]  A. Hercbergs,et al.  Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo. , 1993, International journal of radiation oncology, biology, physics.

[20]  A. Heerschap,et al.  Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. , 1993, The Journal of urology.

[21]  T. Wheeler,et al.  Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. , 1994, The Journal of urology.

[22]  J Roy,et al.  Treatment-related symptoms during the first year following transperineal 125I prostate implantation. , 1994, International journal of radiation oncology, biology, physics.

[23]  B L Miller,et al.  Analysis of brain tumors using 1H magnetic resonance spectroscopy. , 1995, Surgical neurology.

[24]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[25]  J. Saunders,et al.  One-Dimensional Phosphorus-31 Chemical Shift Imaging of Human Brain Tumors , 1995, Investigative radiology.

[26]  C. Wuu,et al.  The effects of sublethal damage recovery and cell cycle progression on the survival probability of cells exposed to radioactive sources. , 1995, The British journal of radiology.

[27]  Bruno Alfano,et al.  1H MR Spectroscopy in Patients with Metastatic Brain Tumors: A Multicenter Study , 1995, Magnetic resonance in medicine.

[28]  P. Carroll,et al.  Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. , 1996, Radiology.

[29]  Y Yu,et al.  A genetic algorithm for the optimization of prostate implants. , 1996, Medical physics.

[30]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[31]  S. Blackband,et al.  Quantification of citrate concentration in the prostate by proton magnetic resonance spectroscopy: Zonal and age‐related differences , 1996, Magnetic resonance in medicine.

[32]  R Oyen,et al.  Cell kinetic measurements in prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[33]  J. Kurhanewicz,et al.  Improved water and lipid suppression for 3D PRESS CSI using rf band selective inversion with gradient dephasing (basing) , 1997, Magnetic resonance in medicine.

[34]  G. Steel,et al.  Basic Clinical Radiobiology , 1997 .

[35]  Eva K. Lee,et al.  Mixed integer programming optimization models for brachytherapy treatment planning , 1997, AMIA.

[36]  A. D'Amico,et al.  Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. , 1997, International journal of radiation oncology, biology, physics.

[37]  A. Renshaw,et al.  Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. , 1997, Urology.

[38]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[39]  M. Zelefsky,et al.  Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. , 1997, The Journal of urology.

[40]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[41]  H. Ragde,et al.  Ten‐year disease free survival after transperineal sonography‐guided iodine‐125 brachytherapy with or without 45‐gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma , 1999, Cancer.

[42]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[43]  R. J. Gallagher,et al.  Treatment planning for brachytherapy: an integer programming model, two computational approaches and experiments with permanent prostate implant planning. , 1999, Physics in medicine and biology.

[44]  L. Potters,et al.  Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. , 1999, The cancer journal from Scientific American.

[45]  Michael J. Zelefsky,et al.  Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer , 1999 .

[46]  J. W. Stallings,et al.  Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity. , 1999, International journal of radiation oncology, biology, physics.

[47]  M. Zaider,et al.  Tumour control probability: a formulation applicable to any temporal protocol of dose delivery. , 2000, Physics in medicine and biology.

[48]  R. Pollock,et al.  Soft Tissue Sarcomas , 2001, CA: a cancer journal for clinicians.